Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 1707-1716

  Dimitropoulos, Konstantinos ^a   Gravas, Stavros ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Benign prostatic hyperplasia; Benign prostatic obstruction; Fixed dose combination; Lower urinary tract symptoms; Overactive bladder; Solifenacin; Tamsulosin

Indexed keywords

PLACEBO; SOLIFENACIN; SOLIFENACIN PLUS TAMSULOSIN; TAMSULOSIN; UNCLASSIFIED DRUG; SULFONAMIDE;

ACUTE URINARY RETENTION; ACUTE URINE RETENTION; BLADDER CAPACITY; CATHETERIZATION; CONSTIPATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; INCIDENCE; LONG TERM CARE; LOWER URINARY TRACT SYMPTOM; OPEN STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); POSTVOID RESIDUAL URINE VOLUME; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TREATMENT OUTCOME; URINE RETENTION; XEROSTOMIA; COMBINATION DRUG THERAPY; COMPLICATION; DOSE RESPONSE; LOWER URINARY TRACT SYMPTOMS; MALE; PROSTATIC HYPERPLASIA;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; PROSTATIC HYPERPLASIA; SOLIFENACIN SUCCINATE; SULFONAMIDES;

EID: 84929145876     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S53184     Document Type: Review

References (54)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.
2. Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118–140.
3. Sexton CC, Coyne KS, Kopp ZS, et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int. 2009;103(Suppl 3):12–23.
4. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–1314; discussion 1314–1315.
5. Chapple CR, Wein AJ, Abrams P, et al. Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol. 2008;54(3):563–569.
6. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49(4):651–658.
7. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology. 2001;58(6 Suppl 1):5–16; discussion 16.
8. Kaplan SA, Roehrborn CG, Chapple CR, et al. Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms. BJU Int. 2009;(103 Suppl 3):48–57.
9. Peters TJ, Donovan JL, Kay HE, et al. The International Continence Society “Benign Prostatic Hyperplasia” Study: the botherosomeness of urinary symptoms. J Urol. 1997;157(3):885–889.
10. Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol. 2009;182(6):2825–2830.
11. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175(3 Pt 1):999–1004; discussion 1004.
12. Kaplan SA, Wein AJ, Staskin DR, Roehrborn CG, Steers WD. Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol. 2008;180(1):47–54.
13. Van Kerrebroeck P, Chapple C, Drogendijk T, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013;64(6):1003–1012.
14. Drake MJ, Chapple C, Sokol R, et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol. Epub July 25, 2014.
15. Morant SV, Reilly K, Bloomfield GA, Chapple C. Diagnosis and treatment of lower urinary tract symptoms suggestive of overactive bladder and bladder outlet obstruction among men in general practice in the UK. Int J Clin Pract. 2008;62(5):688–694.
16. Helfand BT, Evans RM, McVary KT. A comparison of the frequencies of medical therapies for overactive bladder in men and women: analysis of more than 7.2 million aging patients. Eur Urol. 2010;57(4):586–591.
17. Michel MC. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: alpha-blockers in the treatment of male voiding dysfunction–how do they work and why do they differ in tolerability? J Pharmacol Sci. 2010;112(2):151–157.
18. Michel MC, Vrydag W. Alpha1-, alpha2-and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;(147 Suppl 2):S88–S119.
19. Kortmann BB, Floratos DL, Kiemeney LA, Wijkstra H, de la Rosette JJ. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials. Urology. 2003;62(1):1–9.
20. Barendrecht MM, Abrams P, Schumacher H, de la Rosette JJ, Michel MC. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn. 2008;27(3):226–230.
21. Pinggera G-M, Mitterberger M, Steiner E, et al. Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography. BJU Int. 2008;102(4):470–474.
22. Pinggera G-M, Mitterberger M, Pallwein L, et al. alpha-Blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms. BJU Int. 2008;101(3):319–324.
23. Michel MC, Grübbel B, Taguchi K, Verfürth F, Otto T, Kröpfl D. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996;16(1):21–28.
24. Keating GM. Dutasteride/tamsulosin: in benign prostatic hyperplasia. Drugs Aging. 2012;29(5):405–419.
25. Wolzt M, Fabrizii V, Dorner GT, et al. Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple-dose study. Eur J Clin Pharmacol. 1998;54(4):367–373.
26. Miyazawa Y, Blum RA, Schentag JJ, et al. Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function. Curr Ther Res. 2001;62(9):603–621.
27. Michel MC, Mehlburger L, Bressel HU, Schumacher H, Schäfers RF, Goepel M. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol. 1998;160(3 Pt 1):784–791.
28. Guimarães S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev. 2001;53(2):319–356.
29. Rudner XL, Berkowitz DE, Booth JV, et al. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation. 1999;100(23):2336–2343.
30. Martin C, Michel CK. Comparison of vascular α 1adrenoceptor antagonism of tamsulosin in oral controlled absorption system (OCAS) and modified release (MR) formulations. Eur Urol Suppl. 2005;4(2):45–52.
31. Michel MC, Korstanje C, Krauwinkel W, Shear M, Davies J, Quartel A. Cardiovascular safety of the oral controlled absorption system (OCAS) formulation of tamsulosin compared to the modified release (MR) formulation. Eur Urol Suppl. 2005;4(2):53–60.
32. Van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs. 2006;66(3):287–301.
33. Hisasue S, Furuya R, Itoh N, Kobayashi K, Furuya S, Tsukamoto T. Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol. 2006;13(10):1311–1316.
34. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005;31(4):664–673.
35. Abrams P, Andersson K-E. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987–1006.
36. Andersson K-E, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev. 2004;56(4):581–631.
37. Ehlert FJ, Griffin MT, Abe DM, et al. The M2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder. J Pharmacol Exp Ther. 2005;313(1):368–378.
38. Andersson KE. Storage and voiding symptoms: pathophysiologic aspects. Urology. 2003;62(5 Suppl 2):3–10.
39. Andersson K-E. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3(1):46–53.
40. Doroshyenko O, Fuhr U. Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281–302.
41. Ohtake A, Saitoh C, Yuyama H, et al. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull. 2007;30(1):54–58.
42. VESICARE® [product monograph]. Markham, ON: Astellas Pharma Canada, Inc; 2013. Available from: http://www.cmsastellas.ca/uploads/pdf/2013-09-19%20Vesicare-PM-Approved.pdf. Accessed November 1, 2014.
43. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2005;174(6):2273–2275; discussion 2275–2276.
44. Masumori N, Tsukamoto T, Yanase M, Horita H, Aoki M. The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symptoms suggestive of benign prostatic obstruction. Adv Urol. 2010:205251.
45. Yamaguchi O, Kakizaki H, Homma Y, et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms–ASSIST, randomized controlled study. Urology. 2011;78(1):126–133.
46. Van Kerrebroeck P, Haab F, Angulo JC, et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol. 2013;64(3):398–407.
47. Kaplan SA, He W, Koltun WD, Cummings J, Schneider T, Fakhoury A. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol. 2013;63(1):158–165.
48. Lee SH, Byun SS, Lee SJ, Kim KH, Lee JY. Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study. Int Urol Nephrol. 2014;46(3):523–529.
49. Shin YS, Zhang LT, Zhao C, Kim YG, Park JK. Twelve-week, prospective, open-label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add-on therapy to an alpha-blocker for lower urinary tract symptoms. Clin Interv Aging. 2014;9:1021–1030.
50. Yun JH, Kim JH, Kim JH, et al. Can we decide the optimal initial treatment for male lower urinary tract symptoms patients with overactive bladder by the most bothersome symptom? A randomized, prospective, open-label study. Urol Int. 2014;93(3):338–343.
51. Nichol MB, Knight TK, Wu J, Barron R, Penson DF. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol. 2009;181(5):2214–2221; discussion 2221–2222.
52. Lin Y-H, Jiang Y-G, Wang J-S, Luo Y. Finasteride adherence-associated factors in Chinese benign prostatic hyperplasia patients. Urol Int. 2012;88(2):177–182.
53. Van Dulmen S, Sluijs E, van Dijk L, de Ridder D, Heerdink R, Bensing J. Patient adherence to medical treatment: a review of reviews. BMC Health Serv Res. 2007;7:55.
54. Gravas S, Melekos MD. Male lower urinary tract symptoms: how do symptoms guide our choice of treatment? Curr Opin Urol. 2009;19(1):49–54.